Related Experiment Video

Updated: Jun 27, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

Мaryana М Rоsul1, Мyroslava М Bletskan1, Nataliya V Ivano1

  • 1UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|May 1, 2024
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors show promise for acute heart failure (HF) patients. Their unique mechanisms offer improved cardiovascular benefits and better patient prognosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute heart failure (HF) presents significant challenges in patient management and prognosis.
  • Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are emerging as a therapeutic class with potential cardiovascular benefits.

Purpose of the Study:

  • To investigate the mechanisms underlying the cardiovascular benefits of SGLT-2 inhibitors.
  • To explore the potential of SGLT-2 inhibitors in improving treatment and outcomes for acute HF patients.

Main Methods:

  • A comprehensive literature review was conducted.
  • Analysis focused on existing studies evaluating the clinical efficacy and safety of SGLT-2 inhibitors in acute HF.

Main Results:

  • SGLT-2 inhibitors demonstrate favorable cardiovascular effects.
  • Research indicates potential for improved treatment strategies in acute HF.

Conclusions:

  • The pharmacological actions of SGLT-2 inhibitors offer new therapeutic avenues.
  • These agents show encouraging prospects for enhancing the prognosis of hospitalized acute HF patients.
Keywords:
acute heart failuredapagliflozinempagliflozinheart failuresodium-glucose cotransporter 2 (SGLT-2) inhibitors

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.5K

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370